iRhythm Technologies (IRTC)
(Delayed Data from NSDQ)
$71.58 USD
-2.66 (-3.58%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $71.61 +0.03 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.58 USD
-2.66 (-3.58%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $71.61 +0.03 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Zacks News
iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls
by Zacks Equity Research
IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology.
iRhythm Stock Gains Following Favorable Zio Monitor Study Data
by Zacks Equity Research
IRTC announces initial findings demonstrating the superior real-world performance of the next-generation Zio LTCM Monitor at the HRX 2024 meeting.
iRhythm Stock May Gain on Its Latest Deal With BioIntelliSense
by Zacks Equity Research
IRTC announces an exclusive license agreement with BioIntelliSense to develop and commercialize certain patented technology assets within AMC.
iRhythm Technologies Launches Zio Monitoring Across Europe
by Zacks Equity Research
IRTC launches Zio monitor in Austria, Netherlands, Spain and Switzerland, which offers 14-day continuous ECG monitoring, enhancing arrhythmia diagnosis and patient care.
All You Need to Know About iRhythm Technologies (IRTC) Rating Upgrade to Buy
by Zacks Equity Research
iRhythm Technologies (IRTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 33.70% and 1.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
iRhythm Technologies (IRTC) Surges 4.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IRhythm Technologies (IRTC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of -110% and 1.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -23.87% in 4 Weeks, Here's Why iRhythm Technologies (IRTC) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for iRhythm Technologies (IRTC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
IRhythm Technologies (IRTC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
IRhythm Technologies (IRTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iRhythm Technologies (IRTC) Moves 7.4% Higher: Will This Strength Last?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 18.67% and 3.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Schrodinger, Inc. (SDGR) Surges 6.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Schrodinger, Inc. (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of -61.25% and 3.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
American Well Corporation (AMWL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
American Well Corporation (AMWL) delivered earnings and revenue surprises of -20% and 2%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS SA (SOPH) Surges 13.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
iRhythm Technologies (IRTC) Soars 3.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
1Life Healthcare, Inc. (ONEM) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
1Life Healthcare, Inc. (ONEM) delivered earnings and revenue surprises of 5.77% and 0.68%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Azenta (AZTA) Beats Q1 Earnings Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 100% and 1.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Nextgen Healthcare (NXGN) Q3 Earnings Miss Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of -3.70% and 1.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 23.17% and 2.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 15.96% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?